Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma
Open Access
- 20 May 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014408
Abstract
Background: Urothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC, TP53 is recognized not only as a guardian of genomic integrity, but also as a potential architect of the tumor immune microenvironment (TIME). However, how aberrant p53 status, comprising TP53 mutation ( TP53 Mut ) and p53 abnormal expression (p53 Abn ), correlates with TAM phenotypic and functional heterogeneity and their reciprocal interactions within the TIME landscape remains incompletely defined. Methods: This study integrated single-cell RNA sequencing, immunohistochemistry, and flow cytometry to delineate TAM phenotypes and map distinct immune landscapes stratified by p53 status. Clinical relevance was assessed in a multicohort dataset of 962 patients with UC with comprehensive clinicopathological annotations. Results: Single-cell profiling revealed distinct TAM subsets closely linked to p53 status. Interferon-primed TAMs, marked by CXCL9 , CXCL10 , CXCL11 and IDO1 , predominated in p53 wild-type (p53 WT ) tumors, whereas immune regulatory TAMs (Reg-TAMs), marked by SPP1 , MARCO , SLC2A1 and INHBA, were enriched in p53 Abn tumors. This divergent distribution highlighted a profound, p53-associated TAM heterogeneity. Clinically, high TAMs infiltration was consistently associated with worse overall survival predominantly in p53 Abn or TP53 Mut patients across three independent cohorts (Zhongshan Hospital, Fudan University Shanghai Cancer Center and The Cancer Genome Atlas). Furthermore, high TAMs infiltration correlated with poorer responses to both platinum-based chemotherapy and anti-programmed cell death-ligand 1 immunotherapy specifically in the p53 Abn or TP53 Mut subgroup. Notably, aberrant p53 status was strongly coupled with a distinct metabolic reprogramming in TAMs, favoring lipid catabolism and immunoregulatory polarization. Trajectory analysis revealed a skewed differentiation axis in p53 Abn tumors toward terminally differentiated Reg-TAMs. Immunohistochemistry and flow cytometry validated increased immunosuppressive TAM subsets in p53 Abn UC. Additionally, p53 Abn tumors exhibited an altered CD4 + T-cell landscape, enriched for suppressive subsets (regulatory, exhausted, and metallothionein-expressing T cells) coexisting with Reg-TAMs, potentially associated with immune suppression via the predicted SPP1-CD44 axis. Conclusions: In UC, aberrant p53 status correlates with a remodeled TIME, characterized by metabolically reprogrammed, immunosuppressive TAMs. These TAMs co-evolve with suppressive CD4 + T cells, suggesting a coordinated immunosuppressive network potentially involving SPP1-CD44 signaling. Together, this specific genotype-phenotype coupling delineates a profoundly immunosuppressive ecosystem that likely impedes immune clearance and limits therapeutic efficacy.Keywords
Funding Information
- China Postdoctoral Science Foundation (2024M760547)
- China Postdoctoral Science Foundation (2025M781936)
- China Postdoctoral Science Foundation (BX20230091)
- National Natural Science Foundation of China (82272786)
- National Natural Science Foundation of China (82272930)
- National Natural Science Foundation of China (82372793)
- National Natural Science Foundation of China (82373276)
- National Natural Science Foundation of China (8250373)
- National Natural Science Foundation of China (82573675)
- Shanghai Sailing Program (24YF2705400)
- Shanghai Sailing Program (24YF2706000)
- Shanghai Anticancer Association EYAS Project (SACA-CY22B02)
- Shanghai Anticancer Association EYAS Project (SACA-CY24C10)
- Shanghai Anticancer Association EYAS Project (ZYJH202309)
- Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation (YJYQ201802)
- Youth Foundation of Zhongshan Hospital affiliated with Fudan University (ZSZP202405)
- Key Project of Young Doctor Incubation Program of the Second Affiliated Hospital of Army Medical University (2024YQB024)
- Beijing Xisike Clinical Oncology Research Foundation (Y-Gilead2024-PT-0098)
- Shanghai Municipal Health Bureau Project (20224Y0232)
- Shanghai Municipal Health Bureau Project (202340127)
- Shanghai Municipal Health Bureau Project (202340195)
- Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission (24CGA07)
- Natural Science Foundation of Shanghai Municipality (22ZR1413400)
- Natural Science Foundation of Shanghai Municipality (23ZR1411700)
- Natural Science Foundation of Shanghai Municipality (23ZR1440300)
- Natural Science Foundation of Shanghai Municipality (24SF1901304)
- Chongqing Postdoctoral Program for Innovative Talents (CQBX202426)
This publication has 36 references indexed in Scilit:
- Macrophage-mediated myelin recycling fuels brain cancer malignancyCell, 2024
- TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinomaThe Journal of Pathology, 2024
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Mutant p53 suppresses innate immune signaling to promote tumorigenesisCancer Cell, 2021
- TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyCell, 2020
- Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerCell, 2020
- p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsiesThe Journal of Pathology, 2019
- Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent MannerCell, 2019
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis SuppressionCancer Cell, 2016